Literature DB >> 18472962

Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.

Damian J Junk1, Lukas Vrba, George S Watts, Marc M Oshiro, Jesse D Martinez, Bernard W Futscher.   

Abstract

Aberrations of p53 occur in most, if not all, human cancers. In breast cancer, p53 mutation is the most common genetic defect related to a single gene. Immortalized human mammary epithelial cells resemble the earliest forms of aberrant breast tissue growth but do not express many malignancy-associated phenotypes. We created a model of human mammary epithelial tumorigenesis by infecting hTERT-HME1 immortalized human mammary epithelial cells expressing wild-type p53 with four different mutant p53 constructs to determine the role of p53 mutation on the evolution of tumor phenotypes. We demonstrate that different mutant/wild-type p53 heterozygous models generate loss of function, dominant negative activity, and a spectrum of gain of function activities that induce varying degrees of invasive potential. We suggest that this model can be used to elucidate changes that occur in early stages of human mammary epithelial tumorigenesis. These changes may constitute novel biomarkers or reveal novel treatment modalities that could inhibit progression from primary to metastatic breast disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472962      PMCID: PMC2373910          DOI: 10.1593/neo.08120

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  41 in total

1.  Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

Authors:  J Sampath; D Sun; V J Kidd; J Grenet; A Gandhi; L H Shapiro; Q Wang; G P Zambetti; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

2.  Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.

Authors:  Clifford G Tepper; Jeffrey P Gregg; Xu-Bao Shi; Ruth L Vinall; Colin A Baron; Philip E Ryan; Pierre-Yves Desprez; Hsing-Jien Kung; Ralph W deVere White
Journal:  Prostate       Date:  2005-12-01       Impact factor: 4.104

3.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Authors:  Silvia Di Agostino; Sabrina Strano; Velia Emiliozzi; Valentina Zerbini; Marcella Mottolese; Ada Sacchi; Giovanni Blandino; Giulia Piaggio
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

4.  5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.

Authors:  R J Wozniak; W T Klimecki; S S Lau; Y Feinstein; B W Futscher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

5.  Mutant p53 proteins bind DNA abnormally in vitro.

Authors:  S E Kern; K W Kinzler; S J Baker; J M Nigro; V Rotter; A J Levine; P Friedman; C Prives; B Vogelstein
Journal:  Oncogene       Date:  1991-01       Impact factor: 9.867

6.  Tumorigenicity of human breast cancer is associated with loss of the Ca2+-activated chloride channel CLCA2.

Authors:  A D Gruber; B U Pauli
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

Review 7.  Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells.

Authors:  Paul Yaswen; Martha R Stampfer
Journal:  Int J Biochem Cell Biol       Date:  2002-11       Impact factor: 5.085

8.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

9.  Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

Authors:  M Hsiao; J Low; E Dorn; D Ku; P Pattengale; J Yeargin; M Haas
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

Authors:  S Sjögren; M Inganäs; T Norberg; A Lindgren; H Nordgren; L Holmberg; J Bergh
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

View more
  43 in total

1.  p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation.

Authors:  Natalia Artigas; Beatriz Gámez; Mónica Cubillos-Rojas; Cristina Sánchez-de Diego; José Antonio Valer; Gabriel Pons; José Luis Rosa; Francesc Ventura
Journal:  Cell Death Differ       Date:  2017-08-04       Impact factor: 15.828

2.  Ki-67 Contributes to Normal Cell Cycle Progression and Inactive X Heterochromatin in p21 Checkpoint-Proficient Human Cells.

Authors:  Xiaoming Sun; Aizhan Bizhanova; Timothy D Matheson; Jun Yu; Lihua Julie Zhu; Paul D Kaufman
Journal:  Mol Cell Biol       Date:  2017-08-11       Impact factor: 4.272

3.  Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Authors:  Paola Monti; Chiara Perfumo; Alessandra Bisio; Yari Ciribilli; Paola Menichini; Debora Russo; David M Umbach; Michael A Resnick; Alberto Inga; Gilberto Fronza
Journal:  Mol Cancer Res       Date:  2011-02-22       Impact factor: 5.852

4.  Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.

Authors:  Peng Liao; Shelya X Zeng; Xiang Zhou; Tianjian Chen; Fen Zhou; Bo Cao; Ji Hoon Jung; Giannino Del Sal; Shiwen Luo; Hua Lu
Journal:  Mol Cell       Date:  2017-12-07       Impact factor: 17.970

5.  Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.

Authors:  Hongsai Chen; He Huang; Jingjing Zhao; Zhigang Wang; Mengling Chang; Lu Xue; Weidong Zhu; Yongchuan Chai; Gen Li; Zhaoyan Wang; Hao Wu
Journal:  J Neurooncol       Date:  2019-05-02       Impact factor: 4.130

6.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

8.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Authors:  Eva Tonsing-Carter; Barbara J Bailey; M Reza Saadatzadeh; Jixin Ding; Haiyan Wang; Anthony L Sinn; Kacie M Peterman; Tiaishia K Spragins; Jayne M Silver; Alyssa A Sprouse; Taxiarchis M Georgiadis; T Zachary Gunter; Eric C Long; Robert E Minto; Christophe C Marchal; Christopher N Batuello; Ahmad R Safa; Helmut Hanenberg; Paul R Territo; George E Sandusky; Lindsey D Mayo; Christine M Eischen; Harlan E Shannon; Karen E Pollok
Journal:  Mol Cancer Ther       Date:  2015-10-22       Impact factor: 6.261

9.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

10.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.